Leuprolide vs Goserelin

Leuprolide and Goserelin are synthetic GnRH agonists widely investigated in reproductive and cancer research. Despite shared downstream effects on gonadotropin suppression, they diverge in molecular structure, pharmacokinetics, and approved indications. Leuprolide, a nonapeptide, is available in multiple depot formulations, while Goserelin, a decapeptide, is delivered via biodegradable implants. Both induce an initial flare in sex steroid levels followed by sustained suppression, but their evidence bases reflect different emphases: Leuprolide has extensive data in prostate cancer and endometriosis, whereas Goserelin is also studied in breast cancer. This comparison highlights key differences to inform experimental design.

Leuprolide (leuprorelin) is a synthetic GnRH agonist nonapeptide (molecular weight ~1209.4 g/mol) that binds to pituitary GnRH receptors with high affinity. Continuous administration desensitizes these receptors, suppressing luteinizing hormone and follicle-stimulating hormone secretion, thereby reducing gonadal steroid production to castrate levels. This mechanism underpins its FDA-approved uses in advanced prostate cancer, endometriosis, uterine fibroids, central precocious puberty, and assisted reproductive technology. Available as depot injections (monthly, 3-month, 4-month, and 6-month formulations) and subcutaneous implants, leuprolide offers flexible dosing for chronic suppression. Research evidence supports its efficacy as androgen deprivation therapy in prostate cancer, reduction of endometriosis-associated pain, and preoperative shrinkage of uterine fibroids. The initial testosterone flare, lasting 1–2 weeks, is a well-documented phenomenon that may necessitate anti-androgen co-administration in some protocols.

Goserelin is a synthetic decapeptide GnRH agonist (molecular weight ~1269.4 g/mol) formulated as a biodegradable PLGA implant (Zoladex) for subcutaneous injection into the anterior abdominal wall. Its mechanism mirrors that of leuprolide: initial receptor stimulation causes a transient flare in sex steroids, followed by receptor desensitization and profound suppression of gonadotropins and gonadal hormones. FDA-approved indications include advanced prostate cancer, breast cancer (premenopausal), endometriosis, and endometrial thinning prior to ablation. The implant is available in 1-month (3.6 mg) and 3-month (10.8 mg) doses, providing sustained release. Research evidence highlights its role in androgen deprivation for prostate cancer, adjuvant therapy in hormone-sensitive breast cancer, and management of endometriosis-related pain. The flare effect, while transient, can exacerbate tumor-related symptoms in prostate cancer, a consideration in study design.

Both leuprolide and goserelin are extensively studied in reproductive health and cancer treatment, particularly for hormone-sensitive conditions. In reproductive research, they are used to model GnRH agonist-induced suppression of the hypothalamic-pituitary-gonadal axis, with applications in endometriosis, uterine fibroids, and controlled ovarian stimulation protocols. In oncology, both peptides serve as androgen deprivation therapy in prostate cancer and are investigated for their effects on hormone receptor-positive tumors. Notably, goserelin has additional research applications in premenopausal breast cancer, where it suppresses ovarian estrogen production. No unique research applications were identified for leuprolide beyond these shared domains. Researchers should consider the specific delivery systems and pharmacokinetic profiles when selecting between these peptides for experimental models.

Leuprolide: The most common adverse effect is hot flashes/vasomotor symptoms, reported in 55–80% of patients. Prolonged use is associated with bone mineral density loss, limiting treatment duration to 6 months for endometriosis without add-back therapy. The initial testosterone/estrogen flare during the first 1–2 weeks may worsen bone pain or urinary symptoms in prostate cancer, which can be mitigated by concurrent anti-androgen administration. Other considerations include injection site reactions and potential cardiovascular effects. Goserelin: Hot flashes occur in 57–75% of patients, with similar risks of decreased bone mineral density with extended use. The initial disease flare, lasting 1–2 weeks, poses risks of tumor flare in prostate cancer, including spinal cord compression and bone pain exacerbation. Both peptides require monitoring of bone health and management of vasomotor symptoms in long-term studies.